References
- Stern R. S., Nijsten T., Feldman S. R., Margolis D. J., Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136–9
- Rapp S. R., Feldman S. R., Exum M. L., Fleischer A. B., Jr., Reboussin D. M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401–7
- National Psoriasis Foundation. National Psoriasis Foundation: Statistics. National Psoriasis Foundation 2005 [cited 17 August]. URL: http://www.psoriasis.org/about/stats/
- Feldman S. R., Koo J. Y., Menter A., Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol 2005; 53: 101–7
- Feldman S. R., Garton R., Averett W., Balkrishnan R., Vallee J. Strategy to manage the treatment of severe psoriasis: Considerations of efficacy, safety and cost. Expert Opin Pharmacother 2003; 4: 1525–33
- Stern R. S., Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow‐up Study. Cancer 1994; 73: 2759–64
- Griffiths C. E., Clark C. M., Chalmers R. J., Li Wan P. A., Williams H. C. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1–125
- Coven T. R., Burack L. H., Gilleaudeau P., Keogh M., Ozawa M., Krueger J. G. Narrowband UV‐B produces superior clinical and histopathological resolution of moderate to severe psoriasis in patients compared with broadband UV‐B. Arch Dermatol 1997; 133: 1514–22
- Karrer S., Eholzer C., Ackermann G., Landthaler M., Szeimies R. M. Phototherapy of psoriasis: Comparative experience of different phototherapeutic approaches. Dermatology 2001; 202: 108–15
- Housman T. S., Rohrback J. M., Fleischer A. B., Jr., Feldman S. R. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol 2002; 46: 557–9
- Guttman C. NPF/AAD working to increase phototherapy reimbursement. Dermatology Times 2000; 21: 17
- Dalzell M. D. HMOs' delicate balancing act: The art of setting copayments. Manag Care 1997; 6((12))48–50; 53–4
- Cameron H., Yule S., Moseley H., Dawe R. S., Ferguson J. Taking treatment to the patient: Development of a home TL‐01 ultraviolet B phototherapy service. Br J Dermatol 2002; 147: 957–65
- Naldi L., Griffiths C. E. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: An assessment of the benefits and risks. Br J Dermatol 2005; 152: 597–615
- Jenner N., Campbell J., Plunkett A., Marks R. Cost of psoriasis: A study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol 2002; 43: 255–61
- Yelverton C. B., Kulkarni A. S., Balkrishnan R., Feldman S. R. Home ultraviolet B phototherapy: A cost‐effective option for severe psoriasis. Manag Care Interface 2006; 19: 33–6; 39
- Kulkarni A. S., Balkrishnan R., Richmond D. W., Pearce D. J., Feldman S. R. Medication related factors affecting health care outcomes and costs in patients with psoriasis in the United States. J Am Acad Dermatol 2005; 52: 27–31
- Nijsten T., Rolstad T., Feldman S. R., Stern R. S. Members of the National Psoriasis Foundation: More extensive disease and better informed about treatment options. Arch Dermatol 2005; 141: 19–26